Canadian marijuana company has been granted permission by the U.S. federal government to export medicinal cannabis to California for scientific research.
The company, Tilray Inc., and Dr. Fatta Nahab, an associate professor of neurosciences at the University of California San Diego’s medical school, who is behind the research, believe it is the first time that the U.S. Drug Enforcement Administration (DEA) has given the green light to a Canadian producer to export a cannabis study drug south of the border, The Toronto Star reported. Getting approval was a months-long process that also required the U.S. Food and Drug Administration (FDA) to agree.
“It’s quite significant,” Dr. Catherine Jacobson, Tilray’s director of clinical research told the Canadian newspaper. “This is the first time a Canadian (licensed producer) has demonstrated to the FDA that a study drug produced in Canada from the cannabis plant can meet its standards.”
Top photo courtesy of Adobe Stock
Latest from Cannabis Business Times
- Cannabis Industry Reacts to Biden’s Rescheduling Announcement
- As Predicted, 4/20 Sales Surged During Cannabis Industry Holiday Weekend
- DEA 2024 Report Focuses on THC Potency, Organized Crime, Youth Edible Consumption
- Nature's Miracle, Agrify Sign Definitive Merger Agreement
- 5 Things to Confirm When Signing a Cannabis Facility Construction Agreement
- Ziel Partners With Portocanna, Receives 1st EU GMP Certification for Microbial Control Technology in Cannabis
- White House Moves to Reschedule Cannabis in ‘Monumental’ Decision, Biden Says
- SOMAÍ Group, and Its Subsidiary, RPK Biopharma Expand Cookies Partnership to Include Europe and the UK